Health-Related Quality of Life of Premenopausal Women with Breast Cancer Treated with Adjuvant Endocrine Therapy Using Gosereline and Tamoxifen

Health-Related Quality of Life of Premenopausal Women with Breast Cancer Treated with Adjuvant Endocrine Therapy Using Gosereline and Tamoxifen - ZOLTAMQOL

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004695

Enrollment

Registered

2010-12-09

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premenopausal Breast Cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1.Premenopausal women with invasive breast cancer who underwent surgery Definition of premenopause 1-1.Menstruation within one year 1-2.Estradiol and FSH levels are within premenopausal limits 2.Stage I-IIIB (T1-4, N0-2, M0) 3.Estrogen receptor positive 4.Treated with no chemothreapy 5.Planed to be treated with gosereline and tamoxifen 6.Having adequate organ functions 7.PS 0,1 (ECOG) 8.Written informed consent

Exclusion criteria

Exclusion criteria: 1.Suffering other active cancers 2.Having simultaneously diagnosed other cancers or having another invasive cancer diagnosed within past 5 years 3.Ductal carcinoma in situ 4.Inflammatory breast cancer 5.Being pregnant 6.Being treated with LHRH analogue for other diseases 7.having severe menopausal symptoms 8.Being inappropriate by an investigators' decision

Design outcomes

Primary

Measure	Time frame
Changes in FACT-ES and FACT-B scores	—

Secondary

Measure	Time frame
Bone mineral density, Disease-free survival, Adverse events, Calcium intake by questionnaires	—

Countries

Japan

Contacts

Public ContactToshihiro Kai

NPO Saitama Breast Cancer Clinical Study Group (SBCCSG) Executive office (shin-toshin Ladies MammmoClinic)

toshikai@sbccsg.org048-600-1722

Outcome results